| SC 13G/A | 2020-02-14 | Capital World Investors | Adaptimmune Therapeutics PLC | 40,756,200 | 6.4% | EDGAR |
| SC 13G/A | 2019-02-14 | Cross Nicholas John | Adaptimmune Therapeutics PLC | 29,042,800 | 4.6% | EDGAR |
| SC 13G/A | 2019-02-14 | Capital World Investors | Adaptimmune Therapeutics PLC | 40,756,200 | 6.5% | EDGAR |
| SC 13G/A | 2019-01-10 | Matrix Capital Management Company, LP | Adaptimmune Therapeutics PLC | 162,894,000 | 26.0% | EDGAR |
| SC 13D/A | 2018-10-10 | ORBIMED ADVISORS LLC | Adaptimmune Therapeutics PLC | 29,407,858 | 4.7% | EDGAR |
| SC 13G/A | 2018-10-10 | Matrix Capital Management Company, LP | Adaptimmune Therapeutics PLC | 122,172,066 | 19.5% | EDGAR |
| SC 13D | 2018-09-17 | New Enterprise Associates 14, L.P. | Adaptimmune Therapeutics PLC | 94,978,668 | 15.2% | EDGAR |
| SC 13D/A | 2018-03-29 | ORBIMED ADVISORS LLC | Adaptimmune Therapeutics PLC | 30,607,860 | 5.4% | EDGAR |
| SC 13G/A | 2018-02-14 | Matrix Capital Management Company, LP | Adaptimmune Therapeutics PLC | 73,281,066 | 13.0% | EDGAR |
| SC 13G/A | 2018-02-14 | Capital World Investors | Adaptimmune Therapeutics PLC | 40,756,200 | 7.3% | EDGAR |
| SC 13G/A | 2018-02-13 | FMR LLC | Adaptimmune Therapeutics PLC | 27,787,558 | 4.9% | EDGAR |
| SC 13G/A | 2018-02-02 | Cross Nicholas John | Adaptimmune Therapeutics PLC | 29,042,800 | 5.2% | EDGAR |
| SC 13G/A | 2018-02-02 | Laing Ian Michael | Adaptimmune Therapeutics PLC | 20,346,675 | 3.6% | EDGAR |
| SC 13G/A | 2018-02-02 | Robinson George Edward Silvanus | Adaptimmune Therapeutics PLC | 10,596,520 | 1.9% | EDGAR |
| SC 13G/A | 2018-01-29 | New Enterprise Associates 14, L.P. | Adaptimmune Therapeutics PLC | 72,138,996 | 12.8% | EDGAR |
| SC 13D/A | 2018-01-26 | ORBIMED ADVISORS LLC | Adaptimmune Therapeutics PLC | 36,896,260 | 6.6% | EDGAR |
| SC 13G | 2017-09-11 | Matrix Capital Management Company, LP | Adaptimmune Therapeutics PLC | 72,261,066 | 12.9% | EDGAR |
| SC 13G/A | 2017-02-14 | FMR LLC | Adaptimmune Therapeutics PLC | 42,391,084 | 10.0% | EDGAR |
| SC 13G/A | 2017-02-14 | New Enterprise Associates 14, L.P. | Adaptimmune Therapeutics PLC | 59,269,000 | 14.0% | EDGAR |
| SC 13G/A | 2017-02-13 | Capital World Investors | Adaptimmune Therapeutics PLC | 26,882,916 | 6.3% | EDGAR |